Dermatological adverse reactions after vaccination with BNT162b2 in a cohort of healthcare workers.
Ricardo Ruiz VillaverdeMario Rivera-IzquierdoAna Gil-VillalbaMaria D Pegalajar-GarcíaJavier Pérez-RojasEva Soler-IborteM Carmen Valero-UbiernaPublished in: International journal of dermatology (2022)
The rate of dermatological adverse reactions after vaccination with BNT162b2 (Pfizer-BioNTech) is extraordinarily low. No patient required hospitalization, which supports the safety of this vaccination in a population of healthcare workers.
Keyphrases